Meeker David P 4

What Happened

• David P. Meeker, President, CEO and a Director of Rhythm Pharmaceuticals (RYTM), had 68,713 restricted stock units (RSUs convert/vest) on February 1, 2026 (reported as exercises/conversions). Of those, 31,522 shares were withheld/surrendered to pay withholding taxes — reported at $108.99 per share, totaling $3,435,583. Several other vested-share line items (14,125; 21,250; 33,338 shares) are reported as derivative conversions/dispositions at $0 and reflect the mechanics of the RSU vesting and net-settlement/withholding.

Key Details

• Transaction date: February 1, 2026; Form 4 filed February 3, 2026 (filed within the typical 2-business-day window).
• Primary entries: 68,713 shares acquired via conversion/vesting (code M); 31,522 shares disposed/withheld for tax liability (code F) at $108.99/share = $3,435,583.
• Other reported disposals of 14,125; 21,250; and 33,338 shares at $0.00 relate to the vesting/conversion mechanics (surrender/netting) of RSUs.
• Shares owned after the transaction are not listed in the summary provided here.
• Footnotes: These were restricted stock units (each RSU = one share) with multi-year vesting schedules (25% tranches across 2024–2029, per the specific grants). The RSUs have no expiration date.

Context

• This appears to be routine RSU vesting with shares withheld/surrendered to cover tax withholding, not an open-market purchase or speculative sale by the insider. For retail investors, such withholding is a common administrative step when RSUs vest and does not necessarily indicate a bullish or bearish view by the insider.
• Transaction codes: M = exercise/conversion of derivative (here, RSU vesting); F = payment of exercise price or tax liability (withholding/surrender).